Blázquez-Pérez A - Search Results

1

Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison.

Herranz M, Morales-Alcelay S, Corredera-Hernández MT, de la Torre-Alvarado JM, Blázquez-Pérez A, Suárez-Gea ML, Alvarez C, García-Arieta A. Herranz M, et al. Among authors: blazquez perez a. Eur J Clin Pharmacol. 2013 May;69(5):1157-62. doi: 10.1007/s00228-012-1456-6. Epub 2012 Nov 30. Eur J Clin Pharmacol. 2013. PMID: 23196824

2

Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.

García-Arieta A, Morales-Alcelay S, Herranz M, de la Torre-Alvarado JM, Blázquez-Pérez A, Suárez-Gea ML, Alvarez C. García-Arieta A, et al. Among authors: blazquez perez a. Int J Pharm. 2012 Feb 28;423(2):321-5. doi: 10.1016/j.ijpharm.2011.11.022. Epub 2011 Nov 20. Int J Pharm. 2012. PMID: 22120644

3

[Regarding generic antiepileptic drugs].

García-Arieta A, Blázquez-Pérez A, de la Barrera PP, Pozo-Hernández C, Vargas-Castrillón E. García-Arieta A, et al. Among authors: blazquez perez a. Rev Neurol. 2006 Oct 1-15;43(7):446-8; author reply 448. Rev Neurol. 2006. PMID: 17006867 Free article. Spanish. No abstract available.

4

[Interchangeability among therapeutics equivalents of lamotrigine].

Garcia-Arieta A, Blazquez-Perez A. Garcia-Arieta A, et al. Among authors: blazquez perez a. Rev Neurol. 2011 Mar 1;52(5):319-20; author reply 320. Rev Neurol. 2011. PMID: 21341229 Free article. Spanish. No abstract available.

5

[Regulation about generics approval].

Laguna-Goya N, Blázquez-Pérez A, Pozo-Hernández C. Laguna-Goya N, et al. Among authors: blazquez perez a. Farm Hosp. 2006 Nov-Dec;30(6):379-84. doi: 10.1016/s1130-6343(06)74010-7. Farm Hosp. 2006. PMID: 17298196 Review. Spanish.

6

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, Pozo-Hernández C, Vargas-Castrillón E. Gómez-Outes A, et al. Among authors: blazquez perez a. Lancet. 2009 Aug 29;374(9691):682; author reply 683. doi: 10.1016/S0140-6736(09)61552-X. Lancet. 2009. PMID: 19716955 No abstract available.

7

Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?

Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, Pozo-Hernández C, Vargas-Castrillón E. Gómez-Outes A, et al. Among authors: blazquez perez a. J Thromb Haemost. 2009 Dec;7(12):2149-50. doi: 10.1111/j.1538-7836.2009.03618.x. Epub 2009 Sep 18. J Thromb Haemost. 2009. PMID: 19765207 Free article. No abstract available.

8

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

Blázquez-Pérez A, San Miguel R, Mar J. Blázquez-Pérez A, et al. Pharmacoeconomics. 2013 Oct;31(10):919-31. doi: 10.1007/s40273-013-0080-3. Pharmacoeconomics. 2013. PMID: 24000086

9

Estimating chagas disease prevalence and number of underdiagnosed, and undertreated individuals in Spain.

Navarro M, Reguero L, Subirà C, Blázquez-Pérez A, Requena-Méndez A. Navarro M, et al. Among authors: blazquez perez a. Travel Med Infect Dis. 2022 May-Jun;47:102284. doi: 10.1016/j.tmaid.2022.102284. Epub 2022 Mar 2. Travel Med Infect Dis. 2022. PMID: 35245657 Free article.

10

Use of antituberculosis drugs in Spain 1996.

Blázquez Pérez A, Mateos Campos RM. Blázquez Pérez A, et al. Pharmacoepidemiol Drug Saf. 1999 Dec;8(7):523-8. doi: 10.1002/(SICI)1099-1557(199912)8:7<523::AID-PDS459>3.0.CO;2-B. Pharmacoepidemiol Drug Saf. 1999. PMID: 15073896

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page